JAK2 p.Val617Phe (V617F) Mutation Status (Accredited)
Please note that from April 2024 this programme will be consolidated into the Myeloproliferative Neoplasms
Diagnostic Testing programme (Click here) and is no longer available as a stand-alone programme.